Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30124206 | 0.91 | RET (0.32) | RETDGAT2RXRARXRBRXRG | |
| SCHEMBL6508680 | 0.91 | RET (0.32) | RETDGAT2RXRARXRBRXRG | |
| SCHEMBL31089969 | 0.85 | GAA (0.36) | RETDGAT2RXRARXRBRXRG | |
| SCHEMBL20765180 | 0.85 | GAA (0.36) | RETDGAT2RXRARXRBRXRG | |
| SCHEMBL29168077 | 0.85 | IDO1 (0.35) | RETDGAT2RXRARXRBRXRG | |
| SCHEMBL38661414 | 0.82 | RET (0.33) | RETDGAT2 | |
| SCHEMBL657359 | 0.82 | ATR (0.34) | RETDGAT2RXRARXRBRXRG | |
| SCHEMBL14800595 | 0.82 | IDO1 (0.34) | RETDGAT2RXRARXRBRXRG | |
| SCHEMBL38661120 | 0.81 | ATR (0.32) | — | |
| SCHEMBL24805042 | 0.80 | BACE1 (0.32) | RETDGAT2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4536225-A1 | INDAZOLE MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536224-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023240140-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240140-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | NR0B2, NR0B1, ESRRA | RET 403/4885DGAT2 2034/4885RXRA 64/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | RET 1843/4885DGAT2 2860/4885RXRA 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.